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Abstract 
Background: Bodyweight variability is a risk factor for atrial fibrillation (AF). We aimed to examine the relationship 
between bodyweight variability and the risk of AF in patients with type 2 diabetes mellitus (DM), and whether this 
relationship was affected by baseline body mass index (BMI), weight change, or advanced diabetic stage.
Methods: A nationwide population‑based cohort of 670,797 patients with type 2 DM from the Korean National 
Health Insurance Service database without a history of AF and with ≥ 3 measurements of bodyweight over a 5‑year 
period were followed up for AF development. Intra‑individual bodyweight variability was calculated using variability 
independent of mean, and high bodyweight variability was defined as the quintile with the highest variability with 
the lower four quintiles as reference.
Results: During a median of 7.0 years of follow‑up, 22,019 patients (3.3%) newly developed AF. After multivariate 
adjustment, those in the highest quintile of bodyweight variability showed a higher risk of incident AF (HR 1.16, 95% 
CI 1.12–1.20) compared to those in the lower 4 quintiles with reference bodyweight variability, irrespective of baseline 
BMI group and direction of overall weight change. This association was greater in magnitude in subjects with lower 
BMI, those on insulin, and those with a DM duration of greater than 5 years. In sensitivity analyses, high bodyweight 
variability was consistently associated with AF development using other indices of variability and adjusting for glyce‑
mic variability.
Conclusions: High variability in bodyweight was associated with AF development, independently of traditional 
cardiovascular risk factors and baseline BMI. This association was stronger in underweight patients and with advanced 
diabetic stage. Weight fluctuation may interfere with the beneficial effects of weight loss and should be avoided 
when possible in weight control regimens for DM patients.
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Background
Atrial fibrillation (AF) is the most common sustained 
arrhythmia in the general population, and its prevalence 
is progressively increasing [1]. Diabetes mellitus (DM) 
and obesity are both established risk factors for AF [2, 
3]. DM and obesity often coexist, and have synergistic 
effects on the development of AF [4, 5]. Interventions for 
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weight loss lower the risk of AF development or AF bur-
den [6–8], and weight loss is recommended in overweight 
and obese DM patients [9]. However, attempts at weight 
loss are often accompanied by fluctuations in weight, 
with 80% of individuals who intentionally lose > 10% of 
bodyweight often regaining that initial weight loss within 
1 year [10].
Bodyweight fluctuation has been associated with 
increased cardiovascular events and mortality in the gen-
eral population and patients with coronary artery disease 
[11, 12] as well as in DM patients [13, 14]. Bodyweight 
variability has also been associated with an increased risk 
of AF in the general population [15], but this has not been 
studied with a specific focus on the diabetic population.
The purpose of this study was to examine the relation-
ship between bodyweight variability and the risk of AF in 
patients with type 2 DM, and whether this relationship 
was affected by baseline body mass index, weight change, 
or advanced diabetic stage.
Methods
Study population
This study utilized a nationwide population-based claims 
database from the National Health Insurance Service, 
which provides health care insurance coverage and regu-
lar health examinations for the entire Korean population, 
and the details of this database have been described pre-
viously [15, 16]. Data is available to researchers approved 
by their institutional review boards on request at the 
National Health Insurance Sharing Service hompage 
(nhiss.nhis.or.kr). The general population is required 
to undergo government-covered health examinations 
annually or biennially depending on the occupation, and 
the inspection rate is around three-fourths (76.1% from 
a total 17,633,406 subjects scheduled to take the 2015 
health examinations). Patient demographics, all data on 
healthcare usage and prescriptions, health examination 
results, and mortality information are included in the 
database.
The study inclusion flow is shown in Fig.  1. From the 
database, 17,539,992 subjects who underwent health 
examinations in 2009 and 2010 were identified. Subjects 
who underwent ≥ 3 examinations in the previous 5 years 
(from 2004–2005), including the index exam, were 
included (n = 8,376,860). We included adult patients 
with prevalent type 2 DM (age ≥ 30) regardless of the 
onset, and excluded subjects with missing parameters in 
the health examination or with a previous history of AF. 
Subjects under the age of 30 were not included as weight 
gain is part of the natural process of growth in children. 
We ascertained outcome events after a lag of 1 year, and 
those with outcome events within 1 year were excluded 
(n = 4980). Finally, a total of 670,797 subjects with type 2 
DM, and no previous history of AF were included in the 
study.
The index date was the date of the last health examina-
tion, and follow-up was until AF was newly diagnosed, or 
censoring by death, loss of health insurance qualification, 
Fig. 1 Study inclusion flow. DM, diabetes mellitus; AF, atrial fibrillation; Q, quintile
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or end of study (December 31, 2017). Baseline charac-
teristics and health examination results were those of 
the index year. This study was approved by the institu-
tional review board of Seoul National University Hospital 
(E-1811-130-987), and informed consent was waived.
Definitions of diseases and outcome
Patients with DM were defined as follows: (i) having at 
least one claim per year for a prescription of anti-diabetic 
medication under International Statistical Classification 
of Diseases, Tenth Revision (ICD-10) codes E11–14 from 
the insurance claims data, or (ii) having a fasting plasma 
glucose ≥ 126 mg/dL in the health examination without a 
prescription of anti-diabetic medication [4, 17, 18]. Anti-
diabetic medications included sulfonylureas, metformin, 
DPP4 inhibitors, thiazolidinediones, alpha-glucosidase 
inhibitors, meglitinides, and insulins. Patients with type 
1 DM (ICD-10 code E10) were excluded from this study. 
Comorbidities were defined using ICD-10 diagnosis 
codes with health care usage and medication, or health 
examination results, as in the previous studies [15, 19, 
20], and are described in Additional file 1: Table S1. Defi-
nitions of lifestyle behaviors are described in Additional 
file  1: Table  S2. Medications were assessed at the index 
year, and duration of DM was measured from the first 
diagnosis of DM up to the index date.
The primary endpoint was newly-diagnosed nonvalvu-
lar AF. This was defined as the first diagnosis of AF dur-
ing admission or at the outpatient clinic (ICD-10 code 
I48) in the claims database, with the exclusion of rheu-
matic mitral stenosis or prosthetic heart valves [15, 21].
Definition of bodyweight variability
Intra-individual bodyweight variability between visits 
was calculated using variability independent of the mean 
(VIM). VIM is a measure of variability designed not to 
correlate with mean levels and is calculated as SD/meanχ, 
where χ is derived from fitting curves by nonlinear 
regression analysis to SD = constant*meanχ so that there 
is no correlation with the mean [11]. Other measures of 
variability including standard deviation (SD), coefficient 
of variation (CV), average successive variability (ASV) 
[15, 22] were used for sensitivity analyses.
Body mass index (BMI) was calculated as the weight 
(in kilograms) divided by the height (in meters squared). 
Subjects were categorized into 5 groups according to 
BMI: underweight (< 18.5  kg/m2), normal weight (18.5–
22.9  kg/m2), overweight (23–24.9  kg/m2), obese stage I 
(25–29.9 kg/m2), and obese stage II (≥ 30 kg/m2), accord-
ing to World Health Organization recommendations for 
Asians [23]. Overall bodyweight change was the change 
between the first and last health examinations. Subjects 
were categorized according to total bodyweight change 
into 3 groups: weight loss (weight decrease ≥ − 5%), sta-
ble weight (weight change within 5%), and weight gain 
(weight increase ≥ 5%).
Statistical analysis
Continuous variables are presented as mean ± SD, and 
categorical variables as n (%). The incidence rates of AF 
are presented per 1000 person-years. Multivariate Cox 
regression analysis was used to assess the risk of devel-
oping AF associated with bodyweight variability, with 
adjustment for baseline BMI, age, sex, smoking, drink-
ing, exercise, low income, hypertension, dyslipidemia, 
number of oral anti-diabetic medication, insulin use, 
duration of DM, and fasting glucose. The proportional 
hazards assumption was valid for all predictors in graphic 
evaluation of log–log plots. High bodyweight variabil-
ity was defined from the cut-off that AF risk started to 
increase, after evaluation of the relationship between 
bodyweight variability and risk of AF development. Anal-
yses were performed to assess the relationship between 
high bodyweight variability and AF risk based on base-
line BMI categories and overall bodyweight change, using 
Cox regression models with interaction terms. Subgroup 
analyses were conducted for age strata, sex, presence of 
comorbidities, and measures of DM severity. Sensitivity 
analyses were performed using other indices of variability 
(SD, CV, ASV), and with adjustment for glycemic varia-
bility. Statistical analyses were performed using SAS ver-
sion 9.4 (SAS Institute Inc, Cary, NC), and p < 0.05 was 
considered significant.
Results
A total of 670,797 DM patients were followed up for a 
median 7.0 (mean 6.7 ± SD 1.3) years, and 22,019 (3.3%) 
were newly diagnosed with AF (incidence rate 4.9 per 
1000 person-years). Bodyweight was measured in each 
subject, either 3 (74.0%), 4 (12.2%), or 5 times (13.8%). 
The baseline characteristics of the study population are 
shown in Table 1. The mean age was 57.8 years, and 65% 
were men. The mean index bodyweight was 66.5 kg, and 
the mean index BMI was 25.0 kg/cm2. Around two-thirds 
of the subjects were on oral anti-diabetic medication, and 
8% were on insulin.
High bodyweight variability and risk of atrial fibrillation
When the study population was categorized by deciles 
(D) of bodyweight variability, with D1 (lowest variability) 
as reference, there was no significant difference in AF risk 
among D1-8, while D9 showed 11% and D10 showed 20% 
increased risk for incident AF, respectively, in multivari-
able-adjusted analysis (Additional file 1: Fig. S1). There-
fore, we defined “high bodyweight variability” as the top 
20% or the highest quintile (Q) of variability (Q5) with 
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Table 1 Baseline characteristics of the study population according to bodyweight variability
Q, quintile; S(D)BP, Systolic (Diastolic) blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; eGFR, estimated glomerular filtration rate by 
Modification of Diet in Renal Disease equation; SD, standard deviation; CV, coefficient of variation; VIM, variability independent of mean; ASV, average successive 
variability
a Of 6 types of oral medication: sulfonylurea, metformin, meglitinides, thiazolidinediones, DPP4 inhibitor, alpha-glucosidase inhibitor
b Geometric mean (95% CI) due to data not following normal distribution
Total (n = 670,797) Reference bodyweight variability group 
(Q1–4) (n = 536,459)
High bodyweight 
variability group (Q5) 
(n = 134,338)
Age, years 57.80 ± 11.47 57.55 ± 11.15 58.79 ± 12.65
 30–39 years 45433 (6.77) 33665 (6.28) 11768 (8.76)
 40–64 years 436588 (65.08) 359809 (67.07) 76779 (57.15)
 ≥ 65 years 188776 (28.14) 142985 (26.65) 45791 (34.09)
Male 435633 (64.94) 357633 (66.67) 78000 (58.06)
Number of oral anti‑diabetic  medicationa
 0 226812 (33.81) 186815 (34.82) 39997 (29.77)
 1 139300 (20.77) 110250 (20.55) 29050 (21.62)
 2 195051 (29.08) 154610 (28.82) 40441 (30.1)
 3 or more 109634 (16.34) 84784 (15.80) 24850 (18.50)
 Insulin use 51712 (7.71) 36711 (6.84) 15001 (11.17)
 Hypertension 381019 (56.80) 303865 (56.64) 77154 (57.43)
 Dyslipidemia 255584 (38.10) 204328 (38.09) 51256 (38.15)
 Decreased renal function 
(eGFR < 60 mL/min)
76556 (11.43) 58987 (11.01) 17569 (13.09)
Smoking status
 Non‑smoker 364796 (54.38) 286199 (53.35) 78597 (58.51)
 Ex‑smoker 139872 (20.85) 115510 (21.53) 24362 (18.13)
 Current smoker 166129 (24.77) 134750 (25.12) 31379 (23.36)
Drinking status
 Non‑drinker 371857 (55.44) 287962 (53.68) 83895 (62.45)
 Mild drinker 236249 (35.22) 196699 (36.67) 39550 (29.44)
 Heavy drinker 62691 (9.35) 51798 (9.66) 10893 (8.11)
Regular exercise 159100 (23.72) 130269 (24.28) 28831 (21.46)
Low income 157722 (23.51) 124951 (23.29) 32771 (24.39)
Health examination
 Body weight, kg 66.52 ± 11.29 67.03 ± 10.92 64.49 ± 12.45
 Height, cm 162.95 ± 9.07 163.27 ± 8.92 161.66 ± 9.53
 Body mass index, kg/m2 24.97 ± 3.14 25.07 ± 3.01 24.57 ± 3.59
 Waist circumference, cm 85.44 ± 8.14 85.65 ± 7.94 84.63 ± 8.88
 SBP, mmHg 129 ± 15 129 ± 15 128 ± 16
 DBP, mmHg 79 ± 9 79 ± 10 78 ± 10
 Fasting glucose, mg/dL 143 ± 43 142 ± 41 144 ± 50
 Total cholesterol, mg/dL 195.54 ± 40.63 195.92 ± 40.28 194.04 ± 41.95
 HDL‑cholesterol, mg/dL 51.63 ± 21.34 51.47 ± 21.35 52.28 ± 21.26
 LDL‑cholesterol, mg/dL 110.73 ± 44.88 110.85 ± 44.70 110.23 ± 45.58
 Triglycerideb, mg/dL 146.24 (146.04–146.44) 148.26 (148.03–148.49) 138.45 (138.02–138.87)
Weight variability indices
 SD, kg 2.02 ± 1.49 1.49 ± 0.71 4.15 ± 1.85
 CV,  % 3.07 ± 2.26 2.23 ± 1.02 6.41 ± 2.72
 VIM,  % 1.98 ± 1.45 1.44 ± 0.65 4.11 ± 1.74
 ASV, kg 2.31 ± 1.81 1.73 ± 0.95 4.63 ± 2.47
Page 5 of 10Lee et al. Cardiovasc Diabetol           (2020) 19:78  
a VIM cutoff of 2.75, and the rest (Q1–4) as “reference 
bodyweight variability.”
Subjects with high bodyweight variability were slightly 
older (58.8 vs. 57.6  years), less likely to be male, had 
lower bodyweight (64.5 vs. 67.0 kg) and lower BMI (24.6 
vs. 25.0 kg/m2), a higher proportion of hypertension and 
decreased renal function, and more advanced DM with 
higher fasting glucose and a greater number of oral anti-
diabetic medication or insulin use (Table  1). They were 
also less likely to smoke or drink or exercise regularly, and 
more likely to have a lower income. The mean absolute 
bodyweight difference between visits (ASV) was 4.63 kg 
for the high bodyweight variability group and 1.73 kg for 
the reference variability group.
Subjects in the highest quintile of bodyweight variabil-
ity (Q5) showed a significantly higher incidence of AF 
compared to Q1–4, while there was no significant dif-
ference in AF incidence among Q1–4 (Fig. 2a, b). In the 
multivariable-adjusted analysis, subjects with high body-
weight variability had a higher risk of AF development 
(HR 1.16, 95% CI 1.12–1.20) compared to those with ref-
erence bodyweight variability (Fig. 2c).
Subgroup analyses
Incidence rates of AF were higher for subjects with high 
bodyweight variability in all subgroups by age strata, 
sex, presence of obesity, hypertension, or chronic kid-
ney disease, number of oral anti-diabetic medication, 
insulin use, and DM duration. In all subgroup analyses, 
high bodyweight variability was consistently associated 
with AF development, except for similar AF risk in the 
young-age subgroup (Fig.  3). The association between 
high bodyweight variability and AF was significantly 
stronger in non-obese patients (BMI < 25  kg/m2) and 
those with more advanced diabetes, i.e. those on insulin 
or with a DM duration of greater than 5 years (all P for 
interaction < 0.05).
Bodyweight variability and AF risk according to baseline 
BMI
Incidence rates and HRs for AF development showed a 
U-shaped relationship with baseline BMI, with the high-
est risk for AF in the underweight group (HR 1.25, 95% 
CI 1.10–1.42), and the lowest risk for AF in the over-
weight group (HR 0.93, 95% CI 0.89–0.98), in multivari-
able analysis with the normal weight group as reference 
(Additional file  1: Fig.  S2A). AF risk was not signifi-
cantly increased in obese DM patients, though there was 
a tendency for higher AF risk in obese stage II patients 
(BMI ≥ 30 kg/m2).
AF incidence in subjects with reference bodyweight 
variability showed a proportional increase with BMI, with 
the highest AF incidence in the obese group. In contrast, 
AF incidence in subjects with high bodyweight variabil-
ity generally increased with lower BMI, with the highest 
incidence rate of AF in the underweight group (Fig. 4a). 
After multivariable adjustment, high bodyweight vari-
ability was significantly associated with AF development 
in underweight, normal weight, overweight, and obese 
stage I groups. There was a trend of higher AF risk with 
Fig. 2 Atrial fibrillation risk was increased in the highest quintile of bodyweight variability. a, b Subjects in the highest quintile of bodyweight 
variability (Q5) showed significantly higher incidence and risk of AF compared to Q1–4, while there was no significant difference in AF risk among 
Q1–4. c AF risk was 16% increased in high bodyweight variability compared to reference bodyweight variability. Bar graphs represent incidence 
rates per 1000 person‑years with scales on the left. Line graphs with error bars represent the hazard ratios with 95% confidence intervals for atrial 
fibrillation development with scales on the right. Hazard ratios were adjusted for baseline body mass index, age, sex, smoking, drinking, exercise, 
low income, hypertension, dyslipidemia, number of oral anti‑diabetic medication, insulin use, duration of diabetes, and fasting glucose. VIM, 
variability independent of mean; AF, atrial fibrillation; Q, quintile
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higher bodyweight variability in the obese stage II group. 
The association of high bodyweight variability with AF 
became greater in magnitude with lower BMI (P for 
interaction = 0.035), and underweight subjects showed 
a higher risk of AF with high bodyweight variability (HR 
1.28, 95% CI 1.01–1.62). Underweight DM patients with 
high bodyweight variability showed the highest incidence 
rate (7.71 per 1000 person-years) and the highest risk 
for incident AF (HR 1.51, 95% CI 1.29–1.78), compared 
to DM patients with normal weight and reference body-
weight variability (Additional file 1: Table S3).
Bodyweight variability and AF risk according to the overall 
weight change
Incidence rate and HR for AF development were highest 
in subjects with weight loss (HR 1.11, 95% CI 1.08–1.15), 
and similar between subjects with stable weight or weight 
gain, in multivariable analysis with subjects with stable 
weight as reference (Additional file  1: Fig.  S2B). When 
stratified by baseline BMI groups, this trend of higher AF 
risk with only weight loss was consistent in overweight 
and obese patients. In normal-weight or underweight 
patients, there was a tendency for higher AF risk with 
both weight gain and weight loss (Additional file  1: 
Table S4).
Subjects with high bodyweight variability showed 
a higher incidence and risk for AF compared to those 
with reference variability in all weight change groups 
(Fig.  4b). This trend was consistent after stratification 
by BMI into non-obese (BMI < 25) and obese (BMI ≥ 25) 
subjects (Additional file  1: Fig.  S3); the strength of the 
association was greater in the non-obese subjects, which 
was observed in the subgroup analysis. DM patients with 
weight loss and high bodyweight variability showed the 
highest incidence rate (6.14 per 1000 person-years) and 
the highest risk for incident AF (HR 1.20, 95% CI 1.17–
1.27), compared to patients with stable weight and nor-
mal bodyweight variability (Additional file 1: Table S3).
Sensitivity analyses
Sensitivity analyses with other indices of variability, 
i.e. SD, CV, and ASV, also demonstrated a consistent 
Fig. 3 Subgroup analyses for atrial fibrillation risk according to bodyweight variability. Incidence rates (IR) per 1000 person‑years. Hazard ratios 
(HR) were adjusted for baseline body mass index, age, sex, smoking, drinking, exercise, low income, hypertension, dyslipidemia, number of oral 
anti‑diabetic medication, insulin use, duration of diabetes, and fasting glucose. Q, quintile; Bwt, bodyweight; BMI, body mass index; DM, diabetes 
mellitus
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association between high bodyweight variability and risk 
of AF development (Additional file  1: Table  S5). When 
divided by quintiles, there was a steep increase in AF 
risk for Q5 compared to the lower 4 quintiles (Q1–4). In 
line with VIM results, high bodyweight variability (Q5) 
by SD, CV, and ASV was associated with an 18%, 15%, 
and 17% increase in hazard for incident AF, respectively, 
compared to reference bodyweight variability (Q1–4).
Glycemic variability was defined similarly to body-
weight variability from measurements of fasting glu-
cose levels at health examinations done 3–5 times over 
a 5-year period. To note, while this method represents 
longer-term fasting glucose variability, it does not reflect 
short-term oscillations in glucose throughout the day or 
postprandial hyperglycemia. Exploratory analysis further 
adjusting for fasting glycemic variability showed similar 
results to the main analysis (Additional file  1: Table  S6, 
S7). When the study population was divided into deciles 
by glycemic variability, there was no meaningful increase 
in AF risk with high glycemic variability (Additional 
file 1: Table S8).
Discussion
The principal findings of the current study can be sum-
marized as followings: (1) in a large nationwide popu-
lation-based cohort of DM patients, risk of incident AF 
increased in those with the top 20% of bodyweight vari-
ability; these patients with high bodyweight variability 
showed a 16% higher risk of AF development compared 
to the rest of the population independent of traditional 
cardiovascular risk factors and baseline BMI; (2) high 
bodyweight variability was associated with AF develop-
ment regardless of baseline BMI or direction of overall 
weight change; (3) this association was greater in mag-
nitude in patients with lower BMI; underweight patients 
with high bodyweight variability showed the highest risk 
for AF development; and (4) the association between 
high bodyweight variability and AF development was 
consistent in subgroup analyses and was stronger in 
those with more advanced DM, i.e. those on insulin or 
with a DM duration of greater than 5 years.
To the best of our knowledge, this is the first study 
reporting the association of bodyweight variability and 
the risk of AF in patients with type 2 DM.
Bodyweight variability as a risk factor for AF in DM
Weight change has been associated with AF develop-
ment and burden. Obesity predisposes to a larger num-
ber of prolonged AF episodes in the early postoperative 
period after cardiac surgery [24]. In obese patients, bari-
atric surgery with forced weight loss was associated with 
significantly less incidence of AF compared to medically 
managed counterparts [6, 25]. In patients with estab-
lished AF, weight reduction has been associatied with 
lower burden of AF and symptom severity [7, 8, 26].
Weight control is highly recommended to DM patients, 
but dieting and intentional weight control often result 
in weight fluctuation. Weight cycling, or bodyweight 
Fig. 4 Atrial fibrillation risk according to bodyweight variability, stratified by a baseline body mass index and b overall bodyweight change. Bar 
graphs represent incidence rates per 1000 person‑years with scales on the left. Line graphs with error bars represent the hazard ratios with 95% 
confidence intervals for atrial fibrillation development with scales on the right. Hazard ratios were adjusted for baseline body mass index, age, sex, 
smoking, drinking, exercise, low income, hypertension, dyslipidemia, number of oral anti‑diabetic medication, insulin use, duration of diabetes, and 
fasting glucose. Q, quintile
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variability, has been associated with metabolic altera-
tions, cardiovascular events, and death in the general 
population and patients with coronary disease [11, 12, 
27]. We previously demonstrated that bodyweight vari-
ability was an independent predictor of AF in the gen-
eral population [15]. Increasing bodyweight variability 
is associated with higher risks of coronary events, heart 
failure, and death in type 2 DM patients [13, 14]. Herein, 
we demonstrated that high bodyweight variability was 
independently associated with AF development in 
patients with type 2 DM.
Bangalore et  al. showed that greater bodyweight vari-
ability was continuously associated with the risk of coro-
nary or cardiovascular events and death in DM patients, 
and that this association was continuous over the whole 
range of bodyweight variability and was more pro-
nounced in overweight and obese patients [13]. In this 
study, we found that the risk of AF development was 
increased in the top 20% of bodyweight variability, and 
the association between bodyweight variability and AF 
development was more pronounced in underweight DM 
patients after adjustment for baseline BMI.
Of note, there are some differences in the associa-
tion between bodyweight and AF in the diabetic and the 
general population [16]. While the incidence of AF was 
highest for the most obese subjects in the general popu-
lation (3.39 per 1000 person-years), it was highest in the 
diabetic population amongst the underweight subjects 
(5.89 per 1000 person-years). The association between 
bodyweight variability and AF development was greater 
in magnitude with lower BMI in both populations, but 
was more pronounced in the diabetic population (HR 
for high bodyweight variability vs. reference bodyweight 
variability in the underweight group: general population, 
1.16, 95% CI 1.08–1.24; diabetic population, 1.28, 95% CI 
1.01–1.62).
In patients with type 2 DM, overweight and obe-
sity, and weight gain are synergistically associated with 
increased risk of AF [4, 5]. On the other hand, under-
weight and weight loss were associated with increased 
risk for AF [4, 28–30], even after adjustment for base-
line comorbidities. In our study, while there was a trend 
for increased risk of AF with obesity, AF risk was also 
increased with underweight and weight loss, after adjust-
ment for baseline BMI, comorbidities, and lifestyle varia-
bles. One explanation is that while intentional weight loss 
is beneficial, unintentional weight loss may be related to 
hidden chronic diseases and cachexia, which can increase 
AF susceptibility. Other potential hypotheses for the link 
between underweight/weight loss and AF include loss 
of muscle mass, malnutrition, and high adiponectin lev-
els [30–33]. Furthermore, weight loss may be a part of 
weight cycling, and weight regain has been associated 
with rapid adipose tissue accumulation with a higher 
concentration of adipocytes due to altered metabolism 
favoring lipid storage [27], which act as a source of pro-
inflammatory cytokines disposing to cardiac remodeling 
and AF [34].
Patholophysiological implications of bodyweight 
variability
Diabetes is associated with cardiac fibrosis, electri-
cal remodeling, and a higher risk of AF, related to oxi-
dative stress, inflammation, and glycemic fluctuations 
[35]. Insulin resistance is associated with atrial struc-
tural remodeling and abnormal intracellular calcium 
homeostasis, contributing to increased AF susceptibility 
[36]. Obesity is associated with dilatation of the cardiac 
chambers, neurohormonal activation, and electroana-
tomical remodeling of the atria with fibrofatty infiltra-
tion from the epicardial fat [37, 38]. Both diabetes and 
obesity cause expansion of the epicardial adipose tissue, 
the source of proinflammatory adipocytokines which can 
cause microvascular dysfunction and cardiac fibrosis, 
providing the substrate for AF [34]. Weight fluctuation 
resulted in extensive fibro-fatty infiltrations and myolysis 
of the atria that persisted after weight normalization in 
sheep [39]. Weight regain is associated with with rapid 
adipose tissue growth and hyperplasia [27], and weight 
cycling has also been associated with glucose intolerance 
and the development of diabetes [40, 41]. Therefore, the 
combination of diabetes and obesity, especially weight 
cycling, can be synergistic in the development of AF. Glu-
cose fluctuations have also been associated with oxidative 
stress and cardiac fibrosis [42, 43], possibly increasing 
risk of AF development [44]. In our study, bodyweight 
variability was associated with incident AF independent 
of fasting glucose variability.
Interestingly, high bodyweight variability was more 
strongly associated with AF development with advanced 
diabetic stage, suggesting that the pro-arrhythmic effects 
of bodyweight fluctuation and DM may be synergistic. 
Weight cycling may also interfere with the beneficial 
effects of weight loss and could be related to the futil-
ity of intervention focusing on weight loss in reducing 
cardiovascular events [45]. Indeed, our study suggests 
that weight fluctuation can be harmful and should be 
avoided when possible in weight control regimens for 
DM patients.
Strengths and limitations
This study has the following strengths: (1) the large sam-
ple size of 670 thousand patients with type 2 DM; (2) the 
population-based design, minimizing selection bias; and 
(3) the long follow-up duration of median 7 years and the 
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completeness of data, including all health care usage of 
subjects.
Several limitations should also be considered. First, the 
diagnosis of AF was based on claims data, and asymp-
tomatic AF events without hospital visits could not be 
undetected. Also, the types of AF could not be speci-
fied as the database did not include electrocardiograms 
or information on the duration of arrhythmic episodes. 
Second, our analyses did not consider the competing risk 
of death, and the hazard ratios should be interpreted as 
‘AF cause-specific’. Third, whether weight changes were 
intentional or unintentional are not known, and while 
unintentional weight change may be associated with 
underlying disease and adverse outcomes, intentional 
weight change may be beneficial. Fourth, we did not have 
available information on possible confounding factors 
such as baseline cancer. Fifth, while we suggest a syner-
gistic relationship between DM and bodyweight vari-
ability in the process of AF development, the background 
mechanisms warrant further research. Also, the benefit 
of optimal weight control regimens minimizing weight 
fluctuation in DM patients need to be explored in further 
trials.
Conclusions
In a large cohort of patients with type 2 DM, high vari-
ability in bodyweight was associated with AF develop-
ment, independently of traditional cardiovascular risk 
factors and baseline BMI. This association was stronger 
in underweight patients and with advanced diabetic 
stage.
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